There are 2137 resources available
1440P - Safety and efficacy of FLOT regimen neoadjuvant treatment in Polish population: Interim analysis of prospective biomarker study
Presenter: Katarzyna Marcisz-Grzanka
Session: E-Poster Display
Resources:
Abstract
1441P - Outcomes of neoadjuvant chemoradiation (nCRT) +/- surgery and definitive CRT (dCRT) in a single institution using the CROSS trial regimen in esophageal (EC) and gastroesophageal junction cancer (GEJC) in Canada
Presenter: Sidra Khalid
Session: E-Poster Display
Resources:
Abstract
1442P - Association of TMB using the Foundation Medicine Companion Diagnostic (F1CDx) with efficacy of first-line pembrolizumab (pembro) or pembro plus chemotherapy (pembro + chemo) versus chemo in patients with gastric cancer (gc) from KEYNOTE-062
Presenter: Lucjan Wyrwicz
Session: E-Poster Display
Resources:
Abstract
1443P - Modified FOLFOX versus modified FOLFOX plus nivolumab and ipilimumab in patients with previously untreated advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction – Safety Results from AIO-STO-0417: A randomized phase II trial of the German Gastric Group of the AIO
Presenter: Claudia Pauligk
Session: E-Poster Display
Resources:
Abstract
1444P - Real-world nivolumab safety data from 650 patients with unresectable advanced or recurrent gastric cancer that had progressed after cancer chemotherapy: Summary of post-marketing surveillance in Japan
Presenter: Narikazu Boku
Session: E-Poster Display
Resources:
Abstract
1445P - CS1001, an anti-PD-L1 antibody, combined with standard of care (SOC) chemotherapy for first line (1L) advanced GC/GEJ and ESCC: Preliminary results from 2 phase Ib cohorts of CS1001-101 study
Presenter: Lin Shen
Session: E-Poster Display
Resources:
Abstract
1446P - Initial safety and efficacy findings with bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer
Presenter: Ian Chau
Session: E-Poster Display
Resources:
Abstract
1447P - S-1 maintenance therapy in non-Asian patients with advanced, Her-2 negative esophagogastric adenocarcinoma – First results of the international MATEO trial initiated by the AIO
Presenter: Georg Martin Haag
Session: E-Poster Display
Resources:
Abstract
1448P - Paclitaxel and cisplatin combined with anlotinib as first line regimen for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicentre open-label phase II clinical trial
Presenter: Jun-Sheng Wang
Session: E-Poster Display
Resources:
Abstract
1449P - Hospital volume and beyond first-line palliative systemic treatment administration in metastatic esophagogastric adenocarcinoma: A population-based study
Presenter: Willemieke Dijksterhuis
Session: E-Poster Display
Resources:
Abstract